DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-0.12%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$4.54B
AUM Growth
+$4.54B
(-3.1%)
Cap. Flow
-$34.1M
Cap. Flow
% of AUM
-0.75%
Top 10 Holdings %
Top 10 Hldgs %
54.9%
Holding
116
New
14
Increased
17
Reduced
7
Closed
24
Top Buys
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$62.4M |
| 2 |
Centene
CNC
|
$44.2M |
| 3 |
Integra LifeSciences
IART
|
$43M |
| 4 |
Surgery Partners
SGRY
|
$42.7M |
| 5 |
Owens & Minor
OMI
|
$27.3M |
Top Sells
| 1 |
AMED
Amedisys
AMED
|
$164M |
| 2 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$36.8M |
| 3 |
NewAmsterdam Pharma
NAMS
|
$30.1M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$28.5M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$22.7M |
Sector Composition
| 1 | Healthcare | 68.01% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $919M | 20.25% | 19,991,024 | – | – |
|
2
Viatris
VTRS
$12.3B
| $196M | 4.32% | 19,863,485 +2,160,001 | +12% | +$21.3M |
|
|
3
Centene
CNC
$14.3B
| $137M | 3.02% | 1,990,000 +641,000 | +48% | +$44.2M |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $136M | 3% | 1,209,714 | – | – |
|
5
AdaptHealth
AHCO
$1.28B
| $124M | 2.73% | 13,607,940 +2,513,026 | +23% | +$22.9M |
|
|
6
Owens & Minor
OMI
$378M
| $104M | 2.29% | 6,435,000 +1,690,000 | +36% | +$27.3M |
|
7
Catalyst Pharmaceutical
CPRX
$2.52B
| $95.8M | 2.11% | 8,192,000 | – | – |
|
8
Merus
MRUS
$4.98B
| $91.4M | 2.01% | 3,876,938 +845,000 | +28% | +$19.9M |
|
|
DCPH
9
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $87.7M | 1.93% | 6,897,606 +190,580 | +3% | +$2.42M |
|
10
Larimar Therapeutics
LRMR
$310M
| $66.9M | 1.47% | 16,941,357 | – | – |
|
|
11
Bio-Rad Laboratories Class A
BIO
$8.06B
| $62.4M | 1.37% | +173,947 | New | +$62.4M |
|
12
IDEAYA Biosciences
IDYA
$2.15B
| $61.2M | 1.35% | 2,268,628 | – | – |
|
13
Enhabit
EHAB
$399M
| $56.2M | 1.24% | 4,997,746 +187,943 | +4% | +$2.11M |
|
14
HilleVax
HLVX
$105M
| $53.9M | 1.19% | 4,004,231 +675,000 | +20% | +$9.08M |
|
15
Brookdale Senior Living
BKD
$1.83B
| $52.5M | 1.16% | 12,679,651 | – | – |
|
16
Revolution Medicines
RVMD
$7.1B
| $48.5M | 1.07% | 1,751,496 | – | – |
|
|
17
Integra LifeSciences
IART
$1.18B
| $43M | 0.95% | +1,126,827 | New | +$43M |
|
|
18
Surgery Partners
SGRY
$2.91B
| $42.7M | 0.94% | +1,460,000 | New | +$42.7M |
|
19
ARS Pharmaceuticals
SPRY
$1.15B
| $41.9M | 0.92% | 11,077,927 | – | – |
|
20
Kura Oncology
KURA
$686M
| $39.9M | 0.88% | 4,374,044 +1,136,044 | +35% | +$10.4M |
|
21
Guardant Health
GH
$8.41B
| $39.4M | 0.87% | 1,329,935 +75,936 | +6% | +$2.25M |
|
|
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $38.5M | 0.85% | 2,077,893 | – | – |
|
|
SWTX
23
DELISTED
SpringWorks Therapeutics
SWTX
| $36.5M | 0.8% | 1,579,574 +225 | +0% | +$5.2K |
|
24
Cabaletta Bio
CABA
$133M
| $35.6M | 0.78% | 2,340,118 | – | – |
|
|
CMAX
25
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $33.7M | 0.74% | 15,873,213 +12,123 | +0.1% | +$25.7K |
|